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     SUMMARY
INTRODUCTION: Nigeria belongs to the group of countries highly endemic for viral hepatitis, 
unfortunately little is known about the burden of co-infection in HIV positive patients and 
the interaction between these two viruses as it affects the natural history of viral hepatitis, 
management and prevalence.
METHODS: This work was based on the review of medical records of 200 HIV positive patients, 
(130 females and 70 males). Ages: 17-80years at the University of Benin Teaching Hospital, 
Benin city, Nigeria.  
RESULTS: HCV/HBV infection is more serious in HIV- infected patients and this leads to liver 
damage more quickly. It aggravates the risk of antiretroviral (ARD) associated hepatotoxicity. 
HIV is also linked to “sero-silent” HBV infections, which present a problem with diagnosis.
Prevalence of co-infection of 26.9% for HBV which is higher than in HIV negative patients with a 
prevalence of 14.3%. HCV had a prevalence of 5.7%. The prevalence of the test done was found 
to be 25.5% for HBV and 3% for HCV. A prevalence of 17.64% for HBV in HIV positive patients 
and 16.7% for HCV was estimated.    
CONCLUSION: The study confirms that HIV and HBV/HCV interact to a large extent. Therefore 
there is need  to sensitize health workers in Nigeria on the need to take cognizance of this fact 
and improve on the current low level of test conducted on HIV positive patients and vaccination 
done. Early diagnosis and vaccination can prevent mortality due to co-infection.
It is also necessary that studies be carried out on the interaction between HIV and Hepatitis 
virus infection as it affects HAART.
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Introduction
HIV/AIDS pandemic is currently confronting the 
world. Much attention is been paid to the management 
of the disease using drugs in order to prolong the life 
of the victims and help them to lead a normal life.
With this advent of HIV/AIDS, many other infectious 
diseases had also resurfaced creating even more 
challenge to manage and resulting in death of a lot of 
HIV patients on HAART. Examples of such infectious 
disease which has captured much attention all over the 
world including Nigeria is Tuberculosis, but on the 
other hand Viral Hepatitis especially hepatitis B and C 
has not really been paid much attention, either by the 
Government, Health Policy makers, or even Clinicians 
in Nigeria [1].
Co-infection between HBV/HIV and HCV/HIV is 
a state in which an individual is infected with both the 
Human immunodeficiency virus and the Hepatitis B 
or C virus. In other words there is a co-existence of 
both viruses in an individual. Co-infection with human 
immunodeficiency virus (HIV) and hepatitis C virus 
(HCV) and hepatitis B virus (HBV) is a growing public 
health concern. There is growing body of evidence 
about the relevance of viral hepatitis in the frame of 
HIV/AIDS epidemics in Nigeria, and those due to 
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hepatitis B and C viruses are especially note worthy. 
This epidemiological situation has an increasing 
clinical importance [2].
Concomitant disease state is known to interact with 
efficacy of a drug, it is not surprising therefore that there 
is a continued debate on the benefits and strategies of 
anti-viral treatments against hepatotropic viruses in co-
infected patients, there is also a growing concern about 
the possible hepatotoxicity in HIV patient co-infected 
with HBV/HCV receiving HAART and how this could 
result in increase mortality in HIV patients [7].
Because hepatitis B virus are spread in similar 
ways; sex, blood transfusion and use of needles 
notably, new cases of acute HBV infection in persons 
known to have HIV infection could be used to assess 
how the campaign/counseling on the prevention of 
transmission of HIV had been adhered to [3].   
The objective of this work is to review medical 
records of HIV positive patients in University of Benin 
Teaching hospital (UBTH) to ascertain:
-The frequency of co-infection of HIV with HBV/ 
        HCV.
-The level of management of patients co-infected    
        by HIV and HBV/HCV.
-To draw the attention of relevant authorities on  
        the need to carryout more studies on the areas of   
        viral hepatitis in HIV patients.
Materials and methods
Study area
The study was a retrospective study carried out at the 
University of Benin Teaching hospital (UBTH), Benin 
city of Edo state in Nigeria.
The area is known to be warm with a lot of 
rainfall. It is however not known to have the highest 
prevalence of sexually transmitted disease particularly 
HIV infection. 
HIV- positive patient’s case notes.
A review of 200 HIV- positive patients’ case notes 
was done.
This was made up of 130 females and 70 males, 
between 17 -70 years. The case notes used were those 
of patients attending clinic and no case of dead patients 
were included.
Note were taken of the HIV positive and HBV, 
HCV status of each patient, also the CD4 counts were 
also noted.
Ethical approval: 
Approval for the use of the case notes were obtained 
from the ethical committee of the University of Benin 
Teaching Hospital,Benin City. Edo State. 
Results
Prevalence of HBV/HCV test and positive result in 
HIV positive patients:
Of the 200 patient case notes reviewed, 25.5% 
were tested for HBV, 3% tested for HCV, of which 
17.65% were positive for HbsAg and 16.67% for anti 
HCV immunoglobulin. This is shown in Table 1. There 
were more conducted for the female (29.57%) than the 
males (18.57%).
However the males showed a prevalence of 30.77% 
for HbsAg to the females, 23.16%.
More females were also tested for HCV (3.08%), 
than the male (2.86%), of these the only positive test 
was a female. 
CD4 Counts in HIV Positive patients:
Table 2 shows the CD4 counts in HIV positive patients. 
Much improvement was shown among patients 
managed with HAART. A few showed progression of 
HIV infection despite HAART (5 cases) of which 3 
cases were HbsAg positive [7]. 
Table 1:     Prevalence of HBV/HCV test and positive result in HIV    positive patients.
Sex     No     No tested      No tested      % tested  % tested        No. infected No. infected       % infected % infected 
                reviewed         for HBV          for HCV           for HBV for HCV       with HBV with HCV               with HBV  with HCV
Male          70              13                   2                18.57            2.86               4                            0                     30.77                   0
Female     130             38                   4               29.23             3.08              5                             1                    23.16                   25
Total              200                 51                           6                     25.50                  3.00                    9                                        1                           17.65                          16.67
No: indicates number.
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Discussion
In HIV infected patients, co-infection with HCV or 
HBV have been associated with a 
reduced survival rate [4].  
The increased risk of HCV or HBV related 
advanced liver diseases in people with HIV infection 
makes early HBV/HCV diagnosis a priority [5]
Unfortunately this is not so in Nigeria. In this study, 
we established the very low number of HIV patients 
diagnosed for HBV/HCV infection.
The result showed 24.29% for HBV and 2.86% 
for HCV. The reason could be due to the lack of 
information on the effect of HBV/HCV co-infection in 
HIV and the possible liver toxicity among clinicians.   
Analysis of the sex related number of patients that 
undergo test showed that more women were tested 
than men. The obvious reason for this is the higher 
percentage of women that presents in the hospital with 
the disease. The seroprevalence of HBV/HCV amongst 
HIV positive patients showed that the male were more 
infected than the females for hepatitis B virus with a 
prevalence of 30.77%. While for HBV, only one patient 
tested negative. The prevalence of viral hepatitis is 
reported to be higher in males Nigerian than females 
[6], probably due to the higher frequency of exposure 
to infected blood and blood products by the male folks 
as a result of occupation and social behavior.
The age related prevalence of HIV from this study 
shows the highest prevalence among those in their 
fourth decade of life. The reason for this might be as 
a result of latency period of the disease which could 
have been contracted when the patients was a teen or 
young adult and finally manifest the first symptoms 
while in their 30’s.    
Analysis of the CD4 count shows the most prevalent 
at presentation to be between 100-150 cell/uL. At 
this level, HAART ought to have been commenced 
going by CSC recommendation of 200 cells/uL for 
commencement of therapy but for late presentation [7, 8] 
Improvement is largely seen after management 
with HAART, but some cases shows decrease in CD4 
cell count despite HAART, this could be as a result of 
non compliance with ART.  
Conclusion
This study has been able to establish the fact that 
inadequate attention is paid to viral hepatitis infection 
in HIV positive patients.
It is pertinent to also note that a moderate prevalence 
exists for HBV and probably HCV and there is need to 
conduct further studies in this direction.
   
List of abbreviations.
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